Physician profile
Michael P Whyte
NPI 1235168071
$40,283.81
in general payments reported to CMS, 2019-2025
8 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,213 · 2020: $1,500 · 2022: $5,490 · 2023: $7,527 · 2024: $7,350 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $2,477 · Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,045.00 |
| Travel and Lodging | $2,476.77 |
| Food and Beverage | $1,558.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $24,351.13 | 2023-2025 | Crysvita |
| Daiichi Sankyo INC. | $8,089.84 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $6,990.00 | 2020-2022 | |
| Novo Nordisk Health Care Ag | $405.00 | 2024 | |
| Radius Health, INC. | $123.24 | 2019 | |
| Amgen INC. | $115.52 | 2024 | |
| Ascendis Pharma Endocrinology INC | $108.42 | 2023 | |
| Dentsply Sirona Orthodontics INC | $100.66 | 2023 | Suresmile |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Whyte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.